ID

4745

Descripción

Study of CEP-701 in Patients With Acute Myeloid Leukemia (AML) See http://clinicaltrials.gov/ct2/show/study/NCT00079482

Link

http://clinicaltrials.gov/ct2/show/study/NCT00079482

Palabras clave

  1. 18/11/11 18/11/11 -
  2. 26/3/14 26/3/14 - Martin Dugas
  3. 17/9/21 17/9/21 -
Subido en

26 de marzo de 2014

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility NCT00079482 AML

Eligibility AML NCT00079482

  1. StudyEvent: Eligibility
    1. Eligibility AML NCT00079482
Inclusion criteria
Descripción

Inclusion criteria

Alias
UMLS CUI-1
C1512693
cytological confirmation of AML
Descripción

AML

Tipo de datos

boolean

Alias
UMLS CUI-1
C0023467
relapsed disease following first CR of 1 month(30days) to 24 months(730days). The time from first relapse to study entry (start of first course of induction chemotherapy) must be no longer than 30days
Descripción

Relapse

Tipo de datos

boolean

Alias
UMLS CUI-1
C0277556
confirmation of FLT-3 activating mutation positive status after point of initial relapse
Descripción

FLT3 mutation

Tipo de datos

boolean

Alias
UMLS CUI-1
C2348501
aged 18 years or older
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI-1
C0001779
no comorbid conditions that would limit life expectancy to less than 3 months
Descripción

Life expectancy

Tipo de datos

boolean

Alias
UMLS CUI-1
C0023671
ECOG Performance Score of 0, 1,or 2
Descripción

ECOG

Tipo de datos

boolean

Alias
UMLS CUI-1
C1828127
women must be neither pregnant nor lactating, and either of non-childbearing potential or using adequate contraception with a negative pregnancy test at study entry
Descripción

Not pregnant nor lactating

Tipo de datos

boolean

Alias
UMLS CUI-1
C0232973
UMLS CUI-2
C1518422
UMLS CUI-3
C0006147
Exclusion criteria
Descripción

Exclusion criteria

Alias
UMLS CUI-1
C0680251
bilirubin > 2x ULN
Descripción

Bilirubin

Tipo de datos

boolean

Alias
UMLS CUI-1
C0201913
ALT/AST > 3x ULN
Descripción

ALT and AST

Tipo de datos

boolean

Alias
UMLS CUI-1
C0001899
UMLS CUI-2
C0004002
serum creatinine > 1.5 mg/dL
Descripción

Serum creatinine

Tipo de datos

boolean

Alias
UMLS CUI-1
C0201976
resting ejection fraction of left ventricle < 45% (applies only to patients scheduled to receive mitoxantrone, etoposide, and cytarabine (MEC))
Descripción

Ejection fraction (EF)

Tipo de datos

boolean

Alias
UMLS CUI-1
C0232174
untreated or progressive infection
Descripción

Infection

Tipo de datos

boolean

Alias
UMLS CUI-1
C0021311
any physical or psychiatric condition that may compromise participation in the study
Descripción

Major physical or psychiatric condition

Tipo de datos

boolean

known CNS involvement with AML
Descripción

CNS involvement

Tipo de datos

boolean

Alias
UMLS CUI-1
C0449389
any previous treatment with a FLT-3 inhibitor
Descripción

FLT3 inhibitor treatment

Tipo de datos

boolean

Alias
UMLS CUI-1
C0013227
UMLS CUI-2
CL414898
UMLS CUI-3
C1333568
requires current treatment for HIV with protease inhibitors
Descripción

HIV treatment

Tipo de datos

boolean

Alias
UMLS CUI-1
C0019693
active GI ulceration or bleeding
Descripción

Gastrointestinal ulceration or bleeding

Tipo de datos

boolean

Alias
UMLS CUI-1
C0237938
UMLS CUI-2
C0017181
use of an investigational drug that is not expected to be cleared by the start of CEP-701 treatment
Descripción

Other investigational drug

Tipo de datos

boolean

Alias
UMLS CUI-1
C1516879

Similar models

Eligibility AML NCT00079482

  1. StudyEvent: Eligibility
    1. Eligibility AML NCT00079482
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Inclusion criteria
C1512693 (UMLS CUI-1)
AML
Item
cytological confirmation of AML
boolean
C0023467 (UMLS CUI-1)
Relapse
Item
relapsed disease following first CR of 1 month(30days) to 24 months(730days). The time from first relapse to study entry (start of first course of induction chemotherapy) must be no longer than 30days
boolean
C0277556 (UMLS CUI-1)
FLT3 mutation
Item
confirmation of FLT-3 activating mutation positive status after point of initial relapse
boolean
C2348501 (UMLS CUI-1)
Age
Item
aged 18 years or older
boolean
C0001779 (UMLS CUI-1)
Life expectancy
Item
no comorbid conditions that would limit life expectancy to less than 3 months
boolean
C0023671 (UMLS CUI-1)
ECOG
Item
ECOG Performance Score of 0, 1,or 2
boolean
C1828127 (UMLS CUI-1)
Not pregnant nor lactating
Item
women must be neither pregnant nor lactating, and either of non-childbearing potential or using adequate contraception with a negative pregnancy test at study entry
boolean
C0232973 (UMLS CUI-1)
C1518422 (UMLS CUI-2)
C0006147 (UMLS CUI-3)
Item Group
Exclusion criteria
C0680251 (UMLS CUI-1)
Bilirubin
Item
bilirubin > 2x ULN
boolean
C0201913 (UMLS CUI-1)
ALT and AST
Item
ALT/AST > 3x ULN
boolean
C0001899 (UMLS CUI-1)
C0004002 (UMLS CUI-2)
Serum creatinine
Item
serum creatinine > 1.5 mg/dL
boolean
C0201976 (UMLS CUI-1)
Ejection fraction (EF)
Item
resting ejection fraction of left ventricle < 45% (applies only to patients scheduled to receive mitoxantrone, etoposide, and cytarabine (MEC))
boolean
C0232174 (UMLS CUI-1)
Infection
Item
untreated or progressive infection
boolean
C0021311 (UMLS CUI-1)
Major physical or psychiatric condition
Item
any physical or psychiatric condition that may compromise participation in the study
boolean
CNS involvement
Item
known CNS involvement with AML
boolean
C0449389 (UMLS CUI-1)
FLT3 inhibitor treatment
Item
any previous treatment with a FLT-3 inhibitor
boolean
C0013227 (UMLS CUI-1)
CL414898 (UMLS CUI-2)
C1333568 (UMLS CUI-3)
HIV treatment
Item
requires current treatment for HIV with protease inhibitors
boolean
C0019693 (UMLS CUI-1)
Gastrointestinal ulceration or bleeding
Item
active GI ulceration or bleeding
boolean
C0237938 (UMLS CUI-1)
C0017181 (UMLS CUI-2)
Other investigational drug
Item
use of an investigational drug that is not expected to be cleared by the start of CEP-701 treatment
boolean
C1516879 (UMLS CUI-1)

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial